|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yaman S, Gumuskaya B, Ozkan C, Aksoy S,
Guler G and Altundag K: Lymphatic and capillary invasion patterns
in triple negative breast cancer. Am Surg. 78:1238–1242.
2012.PubMed/NCBI
|
|
3
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li W, Ge Z, Liu C, Björkholm M, Jia J and
Xu D: CIP2A is overexpressed in gastric cancer and its depletion
leads to impaired clonogenicity, senescence, or differentiation of
tumor cells. Clin Cancer Res. 14:3722–3728. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ,
Liu YQ, Pu JX, Xiao WL, Sun HD and Zhou GB: Overexpression and
small molecule-triggered downregulation of CIP2A in lung cancer.
PLoS One. 6:e201592011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ren J, Li W, Yan L, Jiao W, Tian S, Li D,
Tang Y, Gu G, Liu H and Xu Z: Expression of CIP2A in renal cell
carcinomas correlates with tumour invasion, metastasis and
patients' survival. Br J Cancer. 105:1905–1911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang J, Li W, Li L, Yu X, Jia J and Chen
C: CIP2A is over-expressed in acute myeloid leukaemia and
associated with HL60 cells proliferation and differentiation. Int J
Lab Hematol. 33:290–298. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lucas CM, Harris RJ, Giannoudis A, Copland
M, Slupsky JR and Clark RE: Cancerous inhibitor of PP2A (CIP2A) at
diagnosis of chronic myeloid leukemia is a critical determinant of
disease progression. Blood. 117:6660–6668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W,
Liu J and Zhou GB: Cancerous inhibitor of PP2A is targeted by
natural compound celastrol for degradation in non-small-cell lung
cancer. Carcinogenesis. 35:905–914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Côme C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tseng LM, Liu CY, Chang KC, Chu PY, Shiau
CW and Chen KF: CIP2A is a target of bortezomib in human triple
negative breast cancer cells. Breast Cancer Res. 14:R682012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen KF, Liu CY, Lin YC, Yu HC, Liu TH,
Hou DR, Chen PJ and Cheng AL: CIP2A mediates effects of bortezomib
on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Oncogene. 29:6257–6266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Memmott RM and Dennis PA: Akt-dependent
and -independent mechanisms of mTOR regulation in cancer. Cell
Signal. 21:656–664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu
YP, Yu XJ, Zhang XD, Ming PH, Zhou GB and Huang L: The natural
compound magnolol inhibits invasion and exhibits potential in human
breast cancer therapy. Sci Rep. 3:30982013.PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu B, Han M, Sun RH, Wang JJ, Zhang YP,
Zhang DQ and Wen JK: ABL-N-induced apoptosis in human breast cancer
cells is partially mediated by c-Jun NH2-terminal kinase
activation. Breast Cancer Research. 12:R92010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Chen XQ, Liang HX, Zhang FX, Zhang
B, Jin J, Chen YL, Cheng YX and Zhou GB: Small compound
6-O-angeloylplenolin induces mitotic arrest and exhibits
therapeutic potentials in multiple myeloma. PLoS One. 6:e219302011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang B, Jiao J, Liu Y, Guo LX, Zhou B, Li
GQ, Yao ZJ and Zhou GB: Gefitinib analogue V1801 induces apoptosis
of T790M egfr-harboring lung cancer cells by up-regulation of the
BH-3 only protein noxa. PLoS One. 7:e487482012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee J, Park EJ, Hwang JW, Oh JM, Kim H,
Bae EK, Choi YL, Han J, Ahn JK, Cha HS and Koh EM: CIP2A expression
is associated with synovial hyperplasia and invasive function of
fibroblast-like synoviocytes in rheumatoid arthritis. Rheumatol
Int. 32:2023–2030. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhai M, Cong L, Han Y and Tu G: CIP2A is
overexpressed in osteosarcoma and regulates cell proliferation and
invasion. Tumour Biol. 35:1123–1128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ha K, Fiskus W, Choi DS, Bhaskara S,
Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM,
et al: Histone deacetylase inhibitor treatment induces 'BRCAness'
and synergistic lethality with PARP inhibitor and cisplatin against
human triple negative breast cancer cells. Oncotarget. 5:5637–5650.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Puustinen P, Rytter A, Mortensen M,
Moreira JM and Jäättelä M: CIP2A oncoprotein controls cell growth
and autophagy through mTORC1 activation. J Cell Biol. 204:713–727.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guffei A, Lichtensztejn Z, Gonçalves Dos
Santos SA, Louis SF, Caporali A and Mai S: c-Myc-dependent
formation of Robertsonian translocation chromosomes in mouse cells.
Neoplasia. 9:578–588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vaqué JP, Fernéndez-García B, García-Sanz
P, Ferrandiz N, Bretones G, Calvo F, Crespo P, Marín MC and León J:
c-Myc inhibits Ras-mediated differentiation of pheochromocytoma
cells by blocking c-Jun up-regulation. Mol Cancer Res. 6:325–339.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Helland A, Anglesio MS, George J, Cowin
PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk
N, Rustgi AK, et al: Deregulation of MYCN, LIN28B and LET7 in a
molecular subtype of aggressive high-grade serous ovarian cancers.
PLoS One. 6:e180642011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma L, Young J, Prabhala H, Pan E, Mestdagh
P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S,
et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin
and cancer metastasis. Nat Cell Biol. 12:247–256. 2010.PubMed/NCBI
|
